Short answer
Indivior Pharmaceuticals, Inc. (INDV) filed an 8-K current report with the SEC on May 15, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 5.07 (Submission of Matters to a Vote of Security Holders). Chief Scientific Officer position eliminated effective June 1, 2026.
Indivior Pharmaceuticals, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Chief Scientific Officer position eliminated effective June 1, 2026
- Dr. Christian Heidbreder retained as CEO advisor for special projects through December 2026
- Employment termination scheduled December 31, 2026, classified as without cause under existing agreement
- Restructuring removes a senior scientific leadership role while preserving temporary project support
Item 5.07 · Submission of Matters to a Vote of Security Holders
- All eight director nominees elected for one-year terms through the 2027 annual meeting
- Say-on-pay approved with 90,364,566 votes for and 1,324,996 against
- Shareholders overwhelmingly favored annual say-on-pay votes, with 91,848,954 votes for one-year frequency
- PwC ratified as independent auditor for fiscal 2026, with 99,146,241 votes for
- 100,407,7225 shares present or represented by proxy out of 121,922,058 entitled to vote
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Indivior Pharmaceuticals, Inc. 8-K filings
Get the next INDV 8-K as it lands
Follow INDV for push alerts, or ask the research agent what this filing means.